Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239678 | 1.00 | TYMP (0.58) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL532674 | 1.00 | TYMP (0.58) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL6905301 | 1.00 | TYMP (0.58) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL22367653 | 0.94 | TYMP (0.65) | TYMPHIF1ASLC29A1ADORA3 | |
| SCHEMBL532504 | 0.91 | HIF1A (0.53) | ADORA1HIF1ASLC29A1PRKAG1PRKAA1 | |
| SCHEMBL18486296 | 0.89 | TYMP (0.56) | TYMPSLC29A1ADORA3 | |
| SCHEMBL14208930 | 0.89 | TYMP (0.45) | TYMPADORA1HIF1ASLC29A1PRKAG1 | |
| SCHEMBL22984001 | 0.89 | TYMP (0.58) | TYMP | |
| SCHEMBL3824088 | 0.89 | TYMP (0.58) | TYMP | |
| SCHEMBL21044306 | 0.89 | TYMP (0.58) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20060040308-A1 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040308-A1 | Compounds and methods for the characterization of oligonucleotides | POLRMT, DCLRE1B, RNGTT | TYMP 43/4885ADORA1 1153/4885HIF1A 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.